Bard J. Geesaman

ProterixBio, Inc. supplies novel protein measurement technology. It manufactures and markets the ViBE platform, enabling highly sensitive, automated acoustic immunoassays to accelerate drug discovery, development and production of biological and pharmaceutical products. The company was founded by Edward F. Crawley and Mark Lundstrom in 2002 and is headquartered in Billerica, MA.

Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. Its products include octreotide capsules. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Needham, MA.

Clinical Ink, Inc. provides electronic source solutions for clinical research sites. Its solutions include data management, monitoring, clinical sites and patient centric. The company was founded by Douglas E. Pierce Jr. and Tommy Littlejohn on July 19, 2006 and is headquartered in Winston-Salem, NC.

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.

Elixir Pharmaceuticals, Inc. operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases such as diabetes and obesity. The company was founded by Leonard Guarente, Cynthia J. Kenyon, Cindy Bayley, Louis Kunkel, Annibale Puca, and Thomas Perls in 1999 and is headquartered in Cambridge, MA.

X PRIZE Foundation creates educational programming for students and space enthusiasts. It offers services in space and ocean exploration, life sciences, energy and environment, education, and global development areas. The company was founded by Peter Diamandis in 1995 and is headquartered in Santa Monica, CA.

F2 Capital Ventures LLP (F2 Ventures) is an Independent Venture Capital firm founded in 2003 by Morana Jovan-Embiricos. The firm is headquartered in the UK.

PharmSelex Corp. (formerly GPC-Rx) focuses on the structure prediction of G-protein coupled receptors (GPCRs) to develop new GPCR-targeting drugs with reduced toxicity and enhanced selectivity. PharmSelex’s technology was developed in the laboratory of Dr. William Goddard at California Institute of Technology. The company is located in Seattle, Washington.